Related references
Note: Only part of the references are listed.Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
Norma A. Palma et al.
CASE REPORTS IN ONCOLOGY (2014)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
Claudia Miranda et al.
CLINICAL CANCER RESEARCH (2012)
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome
A. Pardanani et al.
LEUKEMIA (2012)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status
Nitin Jain et al.
LEUKEMIA RESEARCH (2009)
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
J. Gotlib et al.
LEUKEMIA (2008)
How we diagnose and treat WHO-defined systemic mastocytosis in adults
Ayalew Tefferi et al.
HAEMATOLOGICA (2007)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
Andres C. Garcia-Montero et al.
BLOOD (2006)
Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent
Elizabeth H. Stover et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani et al.
BLOOD (2003)
Share Paper
